Metabolic substrate overload, insulin resistance, lipotoxicity, endoplasmic reticulum stress, inflammasome activation, inflammation, hepatocyte death, and fibrogenesis represent a potential target area of therapy and many are now being evaluated in preclinical studies as well as phase 1, 2, and 3 clinical trials…Read More
Association between non-alcoholic fatty liver disease and risk of new-onset atrial fibrillation in healthy adults.
Previous studies demonstrated conflicting results regarding the association between non-alcoholic fatty liver disease (NAFLD) and atrial fibrillation (AF). The statistical power was not sufficient because of modest sample sizes of these studies. We analyzed a large population-based cohort to evaluate the association between NAFLD and AF…Read More
A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe
In 2018 and 2019, NAFLD experts in 29 European countries completed an English-language survey on policies, guidelines, awareness, monitoring, diagnosis and clinical assessment in their country. The data were compiled, quality checked against existing official documents and reported descriptively…Read More
Increased risk of low bone mineral density in patients with non-alcoholic fatty liver disease: a cohort study.
Non-alcoholic fatty liver disease (NAFLD) has been suggested to be a risk factor associated with low BMD (bone mineral density) in several cross-sectional studies. The present longitudinal cohort study aims to explore the effect of NAFLD and its severity on low BMD. Between January 2013 and August 2018, individuals who participated in annual…Read More